Insights on the Global Genetic Disorders Partnering Industry 2014 to 2020 - Deal Trends, Players and Financials -

DUBLIN--()--The "Global Genetic Disorders Partnering 2014-2020: Deal trends, players and financials" report has been added to's offering.

This report provides the full collection of Genetic Disorders disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

  • Trends in Genetic Disorders partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Genetic Disorders partnering agreement structure
  • Genetic Disorders partnering contract documents
  • Top Genetic Disorders deals by value
  • Most active Genetic Disorders dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genetic Disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genetic Disorders deals.

The report presents financial deal terms values for Genetic Disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Genetic Disorders dealmaking trends.

  • Chapter 1 provides an introduction to the report.
  • Chapter 2 provides an overview of the trends in Genetic Disorders dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
  • Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
  • Chapter 4 provides a review of the leading Genetic Disorders deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Genetic Disorders dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Chapter 5 provides comprehensive access to Genetic Disorders deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
  • Chapter 6 provides a comprehensive directory of all Genetic Disorders partnering deals by specific Genetic Disorders target announced since 2014. The chapter is organized by specific Genetic Disorders therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key Benefits:

  • In-depth understanding of Genetic Disorders deal trends since 2014
  • Access Genetic Disorders deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Genetic Disorders partner companies
  • Comprehensive access to over 470 links to actual Genetic Disorders deals entered into by the world's biopharma companies
  • Indepth review of Genetic Disorders deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Genetic Disorders opportunities
  • Uncover companies actively partnering Genetic Disorders opportunities

Key Topics Covered:

1. Introduction

2. Trends in Genetic Disorders dealmaking

2.1. Introduction

2.2. Genetic Disorders partnering over the years

2.3. Genetic Disorders partnering by deal type

2.4. Genetic Disorders partnering by industry sector

2.5. Genetic Disorders partnering by stage of development

2.6. Genetic Disorders partnering by technology type

2.7. Genetic Disorders partnering by therapeutic indication

3. Financial deal terms for Genetic Disorders partnering

3.1. Introduction

3.2. Disclosed financials terms for Genetic Disorders partnering

3.3. Genetic Disorders partnering headline values

3.4. Genetic Disorders deal upfront payments

3.5. Genetic Disorders deal milestone payments

3.6. Genetic Disorders royalty rates

4. Leading Genetic Disorders deals and dealmakers

4.1. Introduction

4.2. Most active in Genetic Disorders partnering

4.3. List of most active dealmakers in Genetic Disorders

4.4. Top Genetic Disorders deals by value

5. Genetic Disorders contract document directory

5.1. Introduction

5.2. Genetic Disorders partnering deals where contract document available

6. Genetic Disorders dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by Genetic Disorders therapeutic target

Companies Mentioned

  • 4D Molecular Therapeutics
  • AAVLife
  • Abbvie
  • Abby Grace Foundation
  • Abeona Therapeutics
  • AdAlta
  • Addex Therapeutics
  • ADMA Biologics
  • Aequus Pharmaceuticals
  • Affectis Pharmaceuticals
  • Affymetrix
  • Agena Bioscience
  • Agilis Biotherapeutics
  • AGTC
  • AiLife Diagnostics
  • Akcea Therapeutics
  • Alana Healthcare
  • Alcyone Lifesciences
  • Aldeyra Therapeutics
  • Alexion Pharmaceuticals
  • AllCells
  • Allergan
  • Alnylam Pharmaceuticals
  • Altamira Pharma
  • Altius Institute for Biomedical Sciences
  • Ambry Genetics
  • American Heart/Stroke Association
  • American Society of Human Genetics
  • AmerisourceBergen
  • Amgros
  • Amicus Therapeutics
  • AMO Pharma
  • AmorChem
  • Angion Biomedica
  • Annapurna Therapeutics
  • Antabio
  • Anthera Pharmaceuticals
  • ANZAC Reserach Institute
  • AOP Orphan Pharmaceuticals
  • APG Bio
  • Arbor Biotechnologies
  • Arch Biopartners
  • Arcturus Therapeutics
  • Aridis Pharmaceuticals
  • Ariosa Diagnostics
  • ArmaGen
  • ArQule
  • Aruvant Sciences
  • Asklepion Pharmaceuticals
  • Astellas Pharma
  • AstraZeneca
  • Attain Health
  • Auburn University
  • Audentes Therapeutics
  • Bambino Gesu Children's Hospital
  • Bayer
  • And Many Many More Companies!

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900